Ovation Science Inc

KOP Therapeutics is a Vancouver-based biotech company dedicated to developing affordable, non-toxic mRNA cancer treatments that aim to induce cancer cell death with minimal side effects. The company has relocated its research operations from Thomas Jefferson University to streamline the development process and focuses on targeted immunotherapy through its innovative drug platform. Utilizing a novel AI-enabled drug design platform, KOP Therapeutics targets and silences specific cancer genes, enhancing treatment efficacy while sparing healthy cells. Their approach aims to improve patient outcomes and reduce the likelihood of cancer recurrence, with ongoing research in collaboration with leading cancer institutes. Generated from the website

BioNxt Solutions Inc. is a clinical-stage bioscience company based in Vancouver, BC, focused on advancing precision drug delivery technologies, including sublingual and transdermal formulations as well as targeted chemotherapy platforms. With research and development anchored in Germany and partnerships throughout North America and Europe, the company aims to address critical unmet medical needs across neurology, immunology, and oncology. The firm's innovative approaches include a novel drug delivery system that enhances therapeutic precision while reducing systemic toxicity for cancer treatments, and a proprietary library of engineered psychedelic compounds aimed at personalized therapies for neurological, psychiatric, and inflammatory conditions. BioNxt Solutions is committed to improving patient care through advanced drug delivery systems that enhance treatment efficacy and minimize side effects. Generated from the website

Alpha Cognition Inc. is a commercial-stage biopharmaceutical company based in Vancouver, BC, focused on developing treatments for patients suffering from neurodegenerative diseases, including Alzheimer's disease and cognitive impairment related to mild traumatic brain injury. Its lead product, ZUNVEYL (galantamine), is a cholinesterase inhibitor approved for the treatment of mild to moderate dementia of the Alzheimer's type in adults. The company is committed to addressing the challenges of limited treatment options available for such debilitating conditions and actively engages in research and development to advance its pipeline. Alpha Cognition also emphasizes the importance of safety and patient monitoring in its therapeutic approach, reflecting its dedication to improving the lives of those affected by neurodegenerative diseases. Generated from the website